Currently Dr. Belazi is a Practice Leader for Wolters Kluwer Health.  Utilizing patient and medical/pharmacy claims data to conduct marketing, landscape assessments, and outcomes research for pharmaceuticals, devices and other healthcare services.  Previously Dea was a consultant for pharmacy utilization management companies, health plans, PBM's and pharmaceutical companies in the area of managed care and payor marketing, pharmacy benefit management, health outcomes research and formulary strategies.  Also with supporting pharmaceutical companies around strategies for reimbursement both in the US and International markets. He also participates on the Towers Perrin Employer Collaboration P&T Committee, which makes formulary decisions for more than 100 US employers and over 2 million lives.
 
Dr. Belazi was formerly the Senior Director of FutureScripts, which is a wholly owned PBM of Independence Blue Cross and Family of Companies. Dea was responsible for the development, business modeling and strategy of FutureScripts which went live in the summer of 2006.  Dea developed a national pharmacy network, injectable and specialty drug strategy and new operations including call centers, prior authorization department and claims processing.  Dea was integral in developing FutureScripts employer group and Medicare business and marketing strategy.  Prior to FutureScripts Dea was the  Associate Vice President, Clinical Programs for PerformRx and Keystone Mercy and AmeriHealth Mercy Health Plans in Philadelphia, Pennsylvania, also an Independence Blue Cross affiliate, where he also was instrumental in developing and implementing the business model for PerfrormRx.  Dr. Belazi managed the Clinical Programs division, which is comprised of four departments: Prior Authorization, Formulary and DUR, Injectable and Specialty, and Health Outcomes Analysis. Dea was also responsible for the implementation of pharmacy benefit management programs for all new clients.  In his earlier roles, Dea participated in conducting clinical and outcomes research trials for many pharmaceutical companies in multiple disease states such as Rheumatoid Arthritis, Hepatitis C, Alzheimer's and Migraine to name a few. 
 
Dea is a reviewer for numerous publications, including Journal of Managed Care Pharmacy, Value in Health, American Journal of Managed Care and Clinical Therapeutics. He also is an adjunct faculty member at the University of Rhode Island College of Pharmacy and Thomas Jefferson University, Department of Health Policy.
 
Dea received his doctor of pharmacy degree at the University of Rhode Island with a minor in business and marketing.  During his doctoral studies, he spent a year at Brown University, Center for Gerontology, conducting pharmacoepidemiologic research on Alzheimer's disease in the nursing home population.   Dea completed a health economics and outcomes research post-doctoral fellowship at Thomas Jefferson University in Philadelphia and at Abbott Laboratories in Chicago.  Dea also received a master's of public health degree from Johns Hopkins University, School of Public Health.